"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial with an open-label extension that investigates the effect of the addition of dulaglutide (0.75 and 1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baseline in hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus"
2022-06-30
عنوان الدراسة
"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial with an open-label extension that investigates the effect of the addition of dulaglutide (0.75 and 1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baseline in hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus"
داعم الدراسة
Eli Lilly
دواء الدراسة
Dulaglutide 0.75 /1.5 mg
رقم بروتوكول الدراسة
H9X-MC-GBGC
حالة الدراسة
Ongoing
موقع الدراسة
KKUH
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。